Levodopa-induced	levodopa-induced	O	O	O	O
dyskinesias	dyskinesias	O	DISEASE	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
:	:	O	O	O	O
filling	filling	O	O	O	O
the	the	O	O	O	O
bench-to-bedside	bench-to-bedside	O	O	O	O
gap	gap	O	O	O	O
.	.	O	O	O	O

Levodopa	levodopa	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
the	the	O	O	O	O
most	most	O	O	O	O
effective	effective	O	O	O	O
drug	drug	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
long-term	long-term	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
precursor	precursor	O	O	O	O
is	is	O	O	O	O
complicated	complicated	O	O	O	O
by	by	O	O	O	O
highly	highly	O	O	O	O
disabling	disabling	O	O	O	O
fluctuations	fluctuations	O	O	O	O
and	and	O	O	O	O
dyskinesias	dyskinesias	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Although	although	O	O	O	O
preclinical	preclinical	O	O	O	O
and	and	O	O	O	O
clinical	clinical	O	O	O	O
findings	findings	O	O	O	O
suggest	suggest	O	O	O	O
pulsatile	pulsatile	O	O	O	O
stimulation	stimulation	O	O	O	O
of	of	O	O	O	O
striatal	striatal	O	O	O	O
postsynaptic	postsynaptic	O	O	O	O
receptors	receptors	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
key	key	O	O	O	O
mechanism	mechanism	O	O	O	O
underlying	underlying	O	O	O	O
levodopa-induced	levodopa-induced	O	O	O	O
dyskinesias	dyskinesias	O	DISEASE	OTHERS	I
,	,	O	O	O	O
their	their	O	O	O	O
pathogenesis	pathogenesis	O	O	O	O
is	is	O	O	O	O
still	still	O	O	O	O
unclear	unclear	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
recent	recent	O	O	O	O
years	years	O	O	O	O
,	,	O	O	O	O
evidence	evidence	O	O	O	O
from	from	O	O	O	O
animal	animal	O	O	O	O
models	models	O	O	O	O
of	of	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
has	has	O	O	O	O
provided	provided	O	O	O	O
important	important	O	O	O	O
information	information	O	O	O	O
to	to	O	O	O	O
understand	understand	O	O	O	O
the	the	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
specific	specific	O	O	O	O
receptor	receptor	O	O	O	O
and	and	O	O	O	O
post-receptor	post-receptor	O	O	O	O
molecular	molecular	O	O	O	O
mechanisms	mechanisms	O	O	O	O
underlying	underlying	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
dyskinetic	dyskinetic	O	O	OTHERS	I
movements	movements	O	O	OTHERS	I
.	.	O	O	O	O

Recent	recent	O	O	O	O
preclinical	preclinical	O	O	O	O
and	and	O	O	O	O
clinical	clinical	O	O	O	O
data	data	O	O	O	O
from	from	O	O	O	O
promising	promising	O	O	O	O
lines	lines	O	O	O	O
of	of	O	O	O	O
research	research	O	O	O	O
focus	focus	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
differential	differential	O	O	O	O
role	role	O	O	O	O
of	of	O	O	O	O
presynaptic	presynaptic	O	O	O	O
versus	versus	O	O	O	O
postsynaptic	postsynaptic	O	O	O	O
mechanisms	mechanisms	O	O	O	O
,	,	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
receptor	receptor	O	O	O	O
subtypes	subtypes	O	O	O	O
,	,	O	O	O	O
ionotropic	ionotropic	O	O	O	O
and	and	O	O	O	O
metabotropic	metabotropic	O	O	O	O
glutamate	glutamate	CHEMICALS	O	OTHERS	I
receptors	receptors	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
non-dopaminergic	non-dopaminergic	O	O	O	O
neurotransmitter	neurotransmitter	O	O	O	O
systems	systems	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
pathophysiology	pathophysiology	O	O	O	O
of	of	O	O	O	O
levodopa-induced	levodopa-induced	O	O	O	O
dyskinesias	dyskinesias	O	DISEASE	OTHERS	I
.	.	O	O	O	O

